U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H31N5O2.ClH
Molecular Weight 421.964
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUSPIRONE HYDROCHLORIDE

SMILES

Cl.O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)C4=NC=CC=N4

InChI

InChIKey=RICLFGYGYQXUFH-UHFFFAOYSA-N
InChI=1S/C21H31N5O2.ClH/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20;/h5,8-9H,1-4,6-7,10-17H2;1H

HIDE SMILES / InChI

Molecular Formula C21H31N5O2
Molecular Weight 385.5031
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1796057 https://www.ncbi.nlm.nih.gov/pubmed/6151170

Buspirone is the first of a new class of anxioselective agents, the azaspirodecanediones. Animal studies have suggested antianxiety activity and the absence of abuse potential. Behavioural, electrophysiological and receptor binding experiments gradually led to the idea that buspirone owes much of its anxiolytic activity to its ability to attenuate central 5-hydroxytryptamine neurotransmission. In vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT1A) receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. The drug was approved by FDA for the treatment of anxiety.

Originator

Sources: ISBN-13: 978-1285845227

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
24.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BUSPIRONE HYDROCHLORIDE

Approved Use

Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

Launch Date

9.8573759E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.613 ng/mL
15 mg 2 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BUSPIRONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.711 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUSPIRONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.837 ng × h/mL
15 mg 2 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BUSPIRONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.402 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUSPIRONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.062 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUSPIRONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
14%
BUSPIRONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Other AEs: Headache, Asthenia...
Other AEs:
Headache (29 patients)
Asthenia (10 patients)
Accidental injury (16 patients)
Nausea (13 patients)
Dyspepsia (5 patients)
Diarrhea (6 patients)
Vomiting (34 patients)
Lightheadedness (14 patients)
Somnolence (5 patients)
Insomnia (5 patients)
Nervousness (5 patients)
Upper respiratory tract infection (5 patients)
Sources:
15 mg 2 times / day steady, oral
Dose: 15 mg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Spinal Cord Injury
Population Size: 10
Sources:
Other AEs: Nausea, Headache...
Other AEs:
Nausea (below serious, 1 patient)
Headache (below serious, 1 patient)
Fatigue (below serious, 1 patient)
Sources:
20 mg 2 times / day steady, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 19
Sources:
Other AEs: Light headedness...
Other AEs:
Light headedness (below serious, 1 patient)
Sources:
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 88
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 88
Sources:
Other AEs: Lightheadedness, Drowsiness...
Other AEs:
Lightheadedness (below serious, 36 patients)
Drowsiness (below serious, 17 patients)
Gastrointestinal disorder (below serious, 36 patients)
Headache (below serious, 28 patients)
Insomnia (below serious, 16 patients)
Allergic sinusitis (below serious, 13 patients)
Sources:
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Other AEs: Frozen gait, Tremor...
Other AEs:
Frozen gait (below serious, 5 patients)
Tremor (below serious, 3 patients)
Dizziness (below serious, 2 patients)
Fatigue (below serious, 2 patients)
Bradycardia (below serious, 1 patient)
Constipation (below serious, 1 patient)
Dysphagia (below serious, 1 patient)
Gastritis and duodenitis (below serious, 1 patient)
Gastrointestinal disorder (NOS) (below serious, 1 patient)
Cramp in hand (below serious, 1 patient)
Headache (below serious, 1 patient)
Increased agitation (below serious, 1 patient)
Increased appetite (below serious, 1 patient)
Balance impaired NOS (below serious, 1 patient)
Dystonia (below serious, 1 patient)
Irritability (below serious, 1 patient)
Pain in knee (below serious, 1 patient)
Pain (below serious, 1 patient)
Insomnia (below serious, 1 patient)
Joint stiffness (below serious, 1 patient)
Pain neck/shoulder (below serious, 1 patient)
Leg pain (below serious, 1 patient)
Nasal congestion (below serious, 1 patient)
Numbness (below serious, 1 patient)
Infection respiratory (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthenia 10 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Nausea 13 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Lightheadedness 14 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Accidental injury 16 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Headache 29 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Vomiting 34 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Dyspepsia 5 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Insomnia 5 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Nervousness 5 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Somnolence 5 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Upper respiratory tract infection 5 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Diarrhea 6 patients
30 mg 1 times / day steady, oral (median)
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 6–17 years
n = 334
Health Status: unhealthy
Condition: generalized anxiety disorder
Age Group: 6–17 years
Sex: M+F
Population Size: 334
Sources:
Fatigue below serious, 1 patient
15 mg 2 times / day steady, oral
Dose: 15 mg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Spinal Cord Injury
Population Size: 10
Sources:
Headache below serious, 1 patient
15 mg 2 times / day steady, oral
Dose: 15 mg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Spinal Cord Injury
Population Size: 10
Sources:
Nausea below serious, 1 patient
15 mg 2 times / day steady, oral
Dose: 15 mg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg, 2 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Spinal Cord Injury
Population Size: 10
Sources:
Light headedness below serious, 1 patient
20 mg 2 times / day steady, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 19
Sources:
Allergic sinusitis below serious, 13 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 88
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 88
Sources:
Insomnia below serious, 16 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 88
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 88
Sources:
Drowsiness below serious, 17 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 88
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 88
Sources:
Headache below serious, 28 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 88
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 88
Sources:
Gastrointestinal disorder below serious, 36 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 88
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 88
Sources:
Lightheadedness below serious, 36 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 88
Health Status: unhealthy
Condition: Marijuana Dependence
Population Size: 88
Sources:
Balance impaired NOS below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Bradycardia below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Constipation below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Cramp in hand below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Dysphagia below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Dystonia below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Gastritis and duodenitis below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Gastrointestinal disorder (NOS) below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Headache below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Increased agitation below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Increased appetite below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Infection respiratory below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Insomnia below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Irritability below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Joint stiffness below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Leg pain below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Nasal congestion below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Numbness below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Pain in knee below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Pain neck/shoulder below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Pain below serious, 1 patient
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Dizziness below serious, 2 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Fatigue below serious, 2 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Tremor below serious, 3 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Frozen gait below serious, 5 patients
30 mg 2 times / day steady, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: steady
Dose: 30 mg, 2 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 17
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: coadministration of buspirone (10 mg as a single dose) with verapamil (80 mg t.i.d.) or diltiazem (60 mg t.i.d.) increased plasma buspirone concentrations; coadministration of buspirone (10 mg as a single dose) with erythromycin (1.5 g/day for 4 days) increased plasma buspirone concentrations (5-fold increase in Cmax and 6-fold increase in AUC); coadministration of buspirone (10 mg as a single dose) with itraconazole (200 mg/day for 4 days) increased plasma buspirone concentrations (13-fold increase in Cmax and 19-fold increase in AUC); coadministration of buspirone (2.5 or 5 mg b.i.d.) with nefazodone (250 mg b.i.d.) resulted in marked increases in plasma buspirone concentrations (increases up to 20-fold in Cmax and up to 50-fold in AUC); coadministration of buspirone (30 mg as a single dose) with rifampin (600 mg/day for 5 days) decreased the plasma concentrations (83.7% decrease in Cmax; 89.6% decrease in AUC);
Page: 3.0
minor
minor
PubMed

PubMed

TitleDatePubMed
5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.
2000 Dec
Possible serotonin syndrome associated with buspirone added to fluoxetine.
2000 Jul-Aug
Effects of serotoninergic drugs on tremor induced by physostigmine in rats.
2000 May
Strategies for the treatment of antidepressant-related sexual dysfunction.
2001
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.
2001 Aug
Ataxia from lithium toxicity successfully treated with high-dose buspirone: a single-case experimental design.
2001 Aug
Serotonergic regulation of inhibitory avoidance and one-way escape in the rat elevated T-maze.
2001 Dec
The impact of impulsivity on cocaine use and retention in treatment.
2001 Dec
Use of negatively reinforcing electrical brain stimulation to detect conventional and nonconventional anxiolytics as well as an anxiogenic drug.
2001 Jan
Recovery from chronic fatigue syndrome associated with changes in neuroendocrine function.
2001 Jan
Common effects of chronically administered antipanic drugs on brainstem GABA(A) receptor subunit gene expression.
2001 Jul
[New drugs for the treatment of functional dyspepsia].
2001 Jul-Sep
SSRI discontinuation and buspirone.
2001 Jun
Conformational analysis and pharmacophore design for selected 1-(2-pyrimidinyl)piperazine derivatives with sedative-hypnotic activity.
2001 Mar-Apr
Quantifying drug-related 5-HT1A receptor occupancy with.
2001 May
5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential.
2001 May 25
Quantifying the 5-HT1A agonist action of buspirone in man.
2001 Nov
A double-blind placebo-controlled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia--are central serotoninergic responses enhanced?
2001 Oct
Small platform stress increases exploratory activity of mice in staircase test.
2001 Oct
Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury.
2002 Apr
Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex.
2002 Apr
Contact leukoderma caused by buspirone patches.
2002 Mar
Patents

Sample Use Guides

The recommended initial dose is 15 mg daily (7.5 mg b.i.d.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. The maximum daily dosage should not exceed 60 mg per day. In clinical trials allowing dose titration, divided doses of 20 mg to 30 mg per day were commonly employed.
Route of Administration: Oral
In Vitro Use Guide
Buspiron was incubated with hippocampal pyramidal cells at concentration of 50 uM. Buspirone was shown to attenuate the synaptic activation of cells.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:16:39 UTC 2023
Edited
by admin
on Wed Jul 05 23:16:39 UTC 2023
Record UNII
207LT9J9OC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUSPIRONE HYDROCHLORIDE
EP   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
8-AZASPIRO(4,5)DECANE-7,9-DIONE, 8-(4-(4-(2-PYRIMIDINYL)-1-PIPERAZINYL)BUTYL)-, MONOHYDROCHLORIDE
Common Name English
BUSPAR
Brand Name English
BUSPIRONE HYDROCHLORIDE [MART.]
Common Name English
MJ 9022-1
Code English
BUSPIRONE HYDROCHLORIDE [VANDF]
Common Name English
Buspirone hydrochloride [WHO-DD]
Common Name English
BUSPIRONE HYDROCHLORIDE [USP-RS]
Common Name English
BUSPIRONE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
BUSPIRONE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-1,1-cyclopentanediacetamide monohydrochloride
Systematic Name English
APD-405
Code English
BUSPIRONE HCL
Common Name English
APD405
Code English
BUSPIRONE HYDROCHLORIDE [USAN]
Common Name English
NSC-759571
Code English
BUSPIRONE HYDROCHLORIDE [MI]
Common Name English
BUSPIRONE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
NSC-751138
Code English
MJ-9022-1
Code English
BUSPIRONE HYDROCHLORIDE [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28197
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
Code System Code Type Description
RS_ITEM_NUM
1078802
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
NSC
759571
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
MERCK INDEX
M2777
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
251-489-4
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
NSC
751138
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
FDA UNII
207LT9J9OC
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
RXCUI
203116
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID1037193
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
EVMPD
SUB00906MIG
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
ChEMBL
CHEMBL49
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
CAS
33386-08-2
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
SMS_ID
100000091051
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
DAILYMED
207LT9J9OC
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
PUBCHEM
36431
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
CHEBI
3224
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
NCI_THESAURUS
C26641
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
DRUG BANK
DBSALT000313
Created by admin on Wed Jul 05 23:16:39 UTC 2023 , Edited by admin on Wed Jul 05 23:16:39 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Impurity detected at UV 210 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 210 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Impurity detected at UV 210 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
impurity detected at UV 240 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Impurity detected at UV 210 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY